Biogen Idec (BIIB) - FREE Research Report

DiPietro Kenneth who is EVP Human Resources at Biogen Idec sold 1,655 shares at $299.01 on Feb. 5, 2014. Following this transaction, the EVP Human Resources owned 0 shares meaning that the stake was reduced by 100% with the 1,655-share transaction.

The shares most recently traded at $303.54, up $4.53, or 1.49% since the insider transaction. Historical insider transactions for Biogen Idec go as follows:

  • 4-Week # shares sold: 2,020
  • 12-Week # shares sold: 17,459
  • 24-Week # shares sold: 34,385

The average volume for Biogen Idec has been 1.4 million shares per day over the past 30 days. Biogen Idec has a market cap of $72.8 billion and is part of the health care sector and drugs industry. Shares are up 10.23% year-to-date as of the close of trading on Wednesday.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. The company has a P/E ratio of 34.4. Currently there are 14 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIIB - FREE

TheStreet Quant Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Idec Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

When Maids Quit to Trade Stocks

When Maids Quit to Trade Stocks

Market Rides a Chinese Seesaw

Market Rides a Chinese Seesaw

NetScout, Danaher Postpone Deal's Closing Date to Give Regulators More Time

4 Big-Volume Stocks to Trade for Breakouts: Big Lots, Fresh Market and More

JDS Uniphase (JDSU) Stock Gains on Competitor's Quarterly Results and Strong Guidance